Patents Assigned to CENTRE HOSPITALIER UNIVERSITAIRE
-
Patent number: 11525008Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of lung cancer. The inventors showed that FHIT (also known as bis(5-adenosyl)-triphosphatase) regulates HER2 activity in lung tumor cells and that HER2 inhibitors reduce invasion induced by FHIT inhibition. In particular, the present invention relates to a method of treating lung cancer in a patient in need thereof comprising the steps of i) determining the expression level of FHIT in a tumor tissue sample obtained from the patient, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) administering to the patient a therapeutically effective amount of at least one HER2 inhibitor when the expression level determined at step i) is lower than the predetermined reference level.Type: GrantFiled: September 21, 2017Date of Patent: December 13, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE REIMS CHAMPAGNE-ARDENNE, CENTRE HOSPITALIER UNIVERSITAIRE DE REIMSInventors: Béatrice Raby, Amina Jouida, Myriam Polette
-
Patent number: 11499197Abstract: The invention relates to a method for in vitro predicting the outcome of an individual having a multiple myeloma, comprising the steps of: a. measuring the expression level of genes coding for kinases, b. calculating a score value for each genes; and c. classifying the individual as having a good or a bad outcome.Type: GrantFiled: October 30, 2018Date of Patent: November 15, 2022Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITÉ DE MONTPELLIERInventors: Jerome Moreaux, Hugues De Boussac, Alboukadel Kassambara
-
Publication number: 20220351847Abstract: A computer-implemented method for determining a path of a patient in a hospital includes receiving administrative and/or subjective data of the patient; comparing said administrative and subjective data with administrative and subjective data of previously treated patient stored in a database to determine previously treated patients having a given level of similarity with the patient, wherein said database comprises, for each previously treated patient, a recorded path; collecting hospital resources availability data; and determining an initial path of the patient in the hospital wherein said initial path includes calculated probabilities of using specific hospital resources in a given sequence, based on the recorded path of said previously treated patients having said level of similarity with the patient, and said hospital resources availability data.Type: ApplicationFiled: September 16, 2020Publication date: November 3, 2022Applicant: CENTRE HOSPITALIER UNIVERSITAIRE DE NICEInventors: Hervé Haas, Antoine Tran
-
Patent number: 11484529Abstract: The present invention relates to desmethylanethole trithione (AOX) and derivatives thereof, especially derivatives of formula (I), for the prevention and treatment of diseases whose initiation and/or evolution relates to the production and effects of reactive oxygen species (ROS) of mitochondrial origin,Type: GrantFiled: March 7, 2018Date of Patent: November 1, 2022Assignees: OP2 Drugs, Centre Hospitalier Universitaire de Bordeaux, Institut National de la Santé et de la Recherche Médicale (INSERM), Université de BordeauxInventors: Philippe Diolez, Frédéric Marin, Olivier Petitjean
-
Patent number: 11484577Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction. In particular, the present invention relates to a method of treating post-operative cognitive dysfunction in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an APJ receptor agonist.Type: GrantFiled: February 14, 2017Date of Patent: November 1, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSEInventors: Philippe Valet, Cedric Dray, Vincent Minville, Bernard Frances, Francois Labaste, Claire Vinel
-
Patent number: 11479817Abstract: The present invention relates to a method for discriminating an operationally tolerant (TOL) subject from a non-operationally tolerant (STA) subject, comprising the following steps: i) establishing a composite score of tolerance (cSoT) with the expression levels of six genes in a biological sample obtained from said subject and two clinical parameters; wherein said six genes are ID3, AKR1C3, CD40, CTLA4, TCL1A and MZB1, and wherein said cSoT is established by the following formula: cSoT = ? i n ? = ? i × Exprs + ? test ? ? time × age test ? ? time + ? trans ? ? time × age trans ? ? time + intercept - scaling ? ? coefficient ii) comparing this cSoT with a predetermined reference value; and iii) concluding that the subject is TOL when the cSoT is higher than the predetermined reference value or concluding that the subject is STA when the cSoT is lower than the predetermined reference value.Type: GrantFiled: July 21, 2017Date of Patent: October 25, 2022Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, Université de Nantes, Centre Hospitalier Universitaire de Nantes, Centre National de la Recherche ScientifiqueInventors: Richard Danger, Sophie Brouard, Magali Giral, Gérard Ramstein
-
Patent number: 11471538Abstract: The response of subjects suffering from cancer to MAPK inhibitors is dramatically impaired by secondary resistances and rapid relapse. So far, the molecular mechanisms driving these resistances are not completely understood. The inventors show that expression of 10 SLITRK6 (SLIT and NTRK-like family, member 6) is induced by a MAPK inhibitor (e.g. Vemurafenib) and the inhibition of its induction in presence of the MAPK inhibitor induces synthetic lethality. Thus, the only inhibition of SLITRK6 by an inhibitor of activity or expression should potentiate the antitumor effect of the MAPK inhibitors and avoid the emergence of a resistance to those compounds. Furthermore the specific expression of 15 SLITRK6 also paves the way of strategies based on depletion of the residual cancer cells by targeting them with anti-SLITRK6 antibodies capable of mediating ADCC or antibody-drug conjugates binding to SLITRK6.Type: GrantFiled: February 9, 2018Date of Patent: October 18, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTéET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSEInventors: Gilles Favre, Magdalena Pohorecka
-
Patent number: 11464670Abstract: The invention relates to a device for cooling an organ locally, that includes an elongate stem including a far end intended to make contact with an organ to be cooled and comprising including a cooling element having a cold finger, a crystal that has a capacity to cool via excitation at a set excitation wavelength, said crystal being positioned adjacent to said cooling element, an optical guide that is able to convey a light signal at said excitation wavelength and that opens onto said crystal, and an illuminating system including at least one light source, which light source is arranged to emit said light signal.Type: GrantFiled: September 12, 2017Date of Patent: October 11, 2022Assignees: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, UNIVERSITE GRENOBLE ALPES, CENTRE HOSPITALIER UNIVERSITAIRE GRENOBLE ALPESInventors: Nicolas Aubert, Claude Chabrol, Stephan Chabardes, Laurent Duraffourg
-
Patent number: 11460529Abstract: A method and a system automatically perform an image reconstruction of a biological object. The method includes acquiring at different time points t_i signal data for imaging the biological object and clustering a set of data in connection with the acquired signal data. The clustering includes constructing a matrix C, wherein an element Ci,j of the matrix C is the value n_j of one of the data of the dataset acquired at the time point t_i, and then performing a similarity clustering based on the matrix C. At least one of the clusters is selected and determining for each of the time points t_i that are part of the cluster all acquired signal data that have been acquired within a predefined temporal threshold with respect to the considered time point t_i. The image reconstruction of the biological object is performed with the previously determined acquired signal data.Type: GrantFiled: August 10, 2020Date of Patent: October 4, 2022Assignees: Siemens Healthcare GmbH, Centre Hospitalier Universitaire VaudoisInventors: Davide Piccini, John Heerfordt, Christopher Roy, Matthias Stuber
-
Patent number: 11458211Abstract: The present invention relates to compositions and adeno associated viral vectors comprising an optimised HGSNAT nucleic acid sequence of SEQ ID No. 1 or a derivative sequence having at least 77% homology thereof. Uses of such compositions and vectors are also contemplated along with kits of parts for their administration.Type: GrantFiled: July 12, 2017Date of Patent: October 4, 2022Assignees: The University of Manchester, Centre Hospitalier Universitaire Sainte-JustineInventors: Alexey Pchejetsky, Brian Bigger, Claire O'Leary
-
Patent number: 11457900Abstract: The invention relates to a device for capture of cellular biomarkers circulating in an animal or human biological flow, characterised in that it is suitable for use in vivo and in that it comprises a means of filtration intended to retain the said cellular biomarkers, the said means of filtration comprising at least one through-aperture the dimensions of which are suitable for retaining the said cellular biomarkers and being integral with a support, the support taking the form of a hollow component.Type: GrantFiled: February 2, 2016Date of Patent: October 4, 2022Assignees: Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire de Toulouse, Universite Toulouse III—Paul SabatierInventors: Aline Cerf, Sylvain Sanson, Hélène Cayron, Alejandro Kayum Jimenez, Christophe Vieu, Bernard Malavaud
-
Patent number: 11421277Abstract: The present invention relates to a method for predicting the risk of having the CLAD in a subject by measuring the expression level of TCL1A in a biological sample obtained from said subject. Inventors have used a large-scale gene expression profiling of whole blood cells to identify early biomarkers of BOS. Microarray experiments performed from 80 patients (40 stable (STA) and 40 BOS) identified 47 genes differentially expressed between STA and BOS recipients. An independent set of patients (13 STA, 11 BOS) was then used for external validation by qPCR. T-cell leukemia/lymphoma protein 1A (TCL1A) gene was identified and validated as a predictive marker of BOS more than 6 months before diagnosis with area under curve of 0.77. Accordingly, the invention relates to a method for predicting the risk of having the chronic lung allograft dysfunction (CLAD) and to a method for preventing the risk of having CLAD by administering immunosuppressive drugs.Type: GrantFiled: June 26, 2018Date of Patent: August 23, 2022Assignees: INSERM (INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTESInventors: Richard Danger, Sophie Brouard, Pierre-Joseph Royer, Antoine Magnan
-
Patent number: 11406280Abstract: In vitro methods for diagnosing, prognosing and/or monitoring and treating neutrophilic or eosinophilic airway inflammation in a subject, including determining the amount of one or more volatile organic compounds (VOCs) in exhaled breath from said subject. The invention also provides devices for use in said methods.Type: GrantFiled: August 30, 2016Date of Patent: August 9, 2022Assignees: UNIVERSITE DE LIEGE, CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGEInventors: Florence Schleich, Renaud Louis, Kyrylo Bessonov, Kristel Van Steen, Frederik-Jan Van Schooten, Jan Dallinga
-
Publication number: 20220240942Abstract: The invention relates to an intra-aneurysm device (1) for treating an aneurysm (2), comprising a woven structure (S), with meshes made of a plurality of yarns, the woven structure (S) comprising a head (5) intended to be inserted into the aneurysm (2), the head (5) being capable of significantly reducing a blood flow in the aneurysm (2), said head (5) being dome-shaped, the device (1) being characterised in that the woven structure (S) comprises, at a proximal end of said woven structure (S) a knot (4a) connected to the head (5) and in that, at its distal end opposite the proximal end, the head (5) is formed from yarn ends (6a), at least some of which are mechanically connected one another.Type: ApplicationFiled: July 29, 2020Publication date: August 4, 2022Applicants: Universite de Montpellier, Centre Hospitalier Universitaire de Montpellier, Centre National de la Recherche ScientifiqueInventors: Lionel Bichet, Hervé Louche, Franck Jourdan, Vincent Costalat
-
Publication number: 20220227872Abstract: Provided herein are antibodies and antigen-binding portions thereof that bind to tumor endothelial marker 1 (TEM1), as well as methods of using the disclosed antibodies and antigen-binding portions thereof, including methods of treating cancer, reducing tumor growth, reducing tumor metastasis, and/or reducing tumor-associated fibrosis in a subject in need thereof.Type: ApplicationFiled: May 29, 2020Publication date: July 21, 2022Applicants: Ludwig Institute for Cancer Research Ltd, Centre Hospitalier Universitaire Vaudois, Université de LausanneInventors: Steven M. Dunn, Julie K. Fierle, George Coukos
-
Patent number: 11389489Abstract: The present invention relates to pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof. In particular, the present invention relates to a method of inducing satiation in a subject in need thereof comprising administering to the subject an effective amount of a ClpB protein or an effective amount of a bacterium that expresses the ClpB protein.Type: GrantFiled: June 8, 2020Date of Patent: July 19, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN, UNIVERSITE DE ROUEN, TARGEDYSInventors: Serguei Fetissov, Pierre Dechelotte, Jonathan Breton, Gregory Lambert, Naouel Tennoune, Romain Legrand
-
Patent number: 11382894Abstract: The inventors demonstrate that the phosphatase and hydrolase domains of soluble epoxide hydrolase (sEH) regulate the cardiovascular calcification process and revealed that inhibition of the phosphatase domain of sEH could represent a new pharmacological target in the prevention of cardiovascular calcification. The present invention thus relates to a therapeutically effective amount of an inhibitor of phosphatase activity of soluble epoxide hydrolase for use in a method of treating cardiovascular calcification in a subject in need thereof.Type: GrantFiled: March 29, 2018Date of Patent: July 12, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE ROUEN NORMANDIE, UNIVERSITE DE PICARDIE JULES VERNE, CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN, CENTRE HOSPITALIER UNIVERSITAIRE D'AMIENSInventors: Jeremy Bellien, Isabelle Six, Romuald Mentaverri, Said Kamel
-
Patent number: 11376269Abstract: The present invention relates to pharmaceutical compositions for use in the treatment of chemoresistant acute myeloid leukemia (AML). The inventors have established a powerful preclinical model to screen in vivo responses to conventional genotoxics and to mimic the chemoresistance and minimal residual disease as observed in AML patients after chemotherapy. The inventors showed that cytarabine-resistance mechanism involves the CD39-dependent crosstalk between energetic niche and AML mitochondrial functions through CD39-P2Y13-cAMP-PKA signaling axis. In particular, the present invention relates to an inhibitor of the CD39-P2Y13-cAMP-PKA signaling axis for use in a method of treating chemoresistant acute myeloid leukemia (AML) in a patient in need thereof comprising administering to the patient a therapeutically effective amount of said inhibitor.Type: GrantFiled: May 5, 2017Date of Patent: July 5, 2022Assignees: INSERM, UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSEInventors: Jean-Emmanuel Sarry, Christian Recher, Fabienne De Toni-Costes, Nesrine Aroua
-
Patent number: 11369645Abstract: The present invention relates to method of preventing, treating or attenuating obesity-related manifestations in a human or non-human mammal subject in need thereof, said method comprising orally administering to the subject a composition comprising an effective amount Hafnia alvei probiotics; wherein said obesity-related parameters are selected from the group of hyperphagia, increased fat mass on lean mass ratio, increased waist circumference, postprandial hyperglycemia, fasting hyperglycemia and hypercholesterolemia.Type: GrantFiled: June 16, 2020Date of Patent: June 28, 2022Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN, UNIVERSITE DE ROUEN, TARGEDYSInventors: Serguei Fetissov, Pierre Dechelotte, Jonathan Breton, Gregory Lambert, Nicolas Lucas, Romain Legrand
-
Patent number: D965175Type: GrantFiled: February 24, 2021Date of Patent: September 27, 2022Assignees: UNIVERSITE DE VERSAILLES—SAINT QUENTIN EN YVELINES, CENTRE HOSPITALIER INTERCOMMUNAL DE POISSY-SAINT-GERMAIN, CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, UNIVERSITE DE BORDEAUX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: François Vialard, Clément Jimenez, Christophe Geindre, Bruno Hiberty, Hugo Ducros